Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Go back to Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 229.85 -0.4 (0.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.25 | 52 Week High | $160.00 | |||
| Open | $229.76 | 52 Week Low | $95.80 | |||
| Day High | $234.08 | P/E | 42.72 | |||
| Day Low | $228.30 | EPS | $5.38 | |||
| Volume | 742,376 | |||||
